Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Sponsor: Profound Medical Inc.
A NA clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Profound Medical Inc. and has accumulated 11 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Mar 2020 — Jan 2021 [monthly]
Completed NA
-
Jul 2019 — Mar 2020 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Jun 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Phase: PHASE1 → NA
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Profound Medical Inc.
For direct contact, visit the study record on ClinicalTrials.gov .